Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Soluble TNF receptors and their use in treatment of disease

a technology of soluble tnf receptors and tnf receptors, which is applied in the direction of peptides, drug compositions, peptides, etc., can solve the problems of not responding to currently approved treatments, and achieve the effect of increasing the level of a soluble tnfr

Inactive Publication Date: 2011-05-05
SANTARIS PHARMA AS +2
View PDF28 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, there are patients who do not respond to currently approved TNF-α antagonists.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Soluble TNF receptors and their use in treatment of disease
  • Soluble TNF receptors and their use in treatment of disease
  • Soluble TNF receptors and their use in treatment of disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0154]Oligonucleotides. Table 3 lists chimeric locked nucleic acid (LNA) SSOs with alternating 2′ deoxy- and 2′O-4′-(methylene)-bicyclic-ribonucleoside-phosphorothioates and having sequences as described in U.S. application Ser. No. 11 / 595,485. These were synthesized by Santaris Pharma, Denmark. For each SSO, the 5′-terminal nucleoside was a 2′O-4′-methylene-ribonucleoside and the 3′-terminal nucleoside was a 2′ deoxy-ribonucleoside. Table 4 shows the sequences of chimeric LNA SSOs with alternating 2′-O-methyl-ribonucleoside-phosphorothioates (2′-OMe) and 2′O-4′-(methylene)-bicyclic-ribonucleoside phosphorothioates. These were synthesized by Santaris Pharma, Denmark. The LNA is shown in capital letters and the 2′-OME is shown in lower case letters.

[0155]Cell culture and transfections. L929 cells were maintained in minimal essential media supplemented with 10% fetal bovine serum and antibiotic (37° C., 5% CO2). For transfection, L929 cells were seeded in 24-well ...

example 2

SSO Splice Switching Activity with TNFR mRNA

[0165]Table 3 shows the splice switching activities of SSOs having sequences as described in U.S. application Ser. No. 11 / 595,485 and targeted to mouse and human TNFRs. Of SSOs targeted to mouse TNFR2 exon 7, at least 8 generated some muTNFR2 Δ7 mRNA. In particular, SSO 3312, 3274 and 3305 induced at least 50% skipping of exon 7; SSO 3305 treatment resulted in almost complete skipping. Of SSOs transfected into primary human hepatocytes, and targeted to human TNFR2 exon 7, at least 7 SSOs generated some huTNFR2 Δ7 mRNA. In particular, SSOs 3378, 3379, 3384 and 3459 induced at least 75% skipping of exon 7 (FIG. 2B), and significant induction of huTNFR2 Δ7 into the extracellular media (FIG. 2A).

TABLE 3SSO Splice Switching ActivitySEQ ID.NameActivityMouse TNFR23272−3304−3305+3306+3307+3308+3309+3310−3311+623274+3312+3273−Mouse TNFR13333+Human TNFR2143378+303379+3380−703381+713382+3383−463384+723459+3460−733461+Control3083−

[0166]Table 4 contain...

example 3

Analysis of the Splice Junction of SSO-Induced TNFR2Splice Variants

[0171]To confirm that the SSO splice switching, both in mice and in human cells, leads to the expected TNFR2 Δ7 mRNA, SSO-induced TNFR2 Δ7 mRNA was analyzed by RT-PCR and was sequenced.

[0172]Mice. Mice were injected with SSO 3274 intraperitoneal (i.p.) at 25 mg / kg / day for 10 days. The mice were then sacrificed and total RNA from the liver was analyzed by RT-PCR using the forward primer TR045 (SEQ ID No: 112) and the reverse primer TR046 (SEQ ID No: 113). The products were analyzed on a 1.5% agarose gel (FIG. 6A) and the product for the TNFR2 Δ7 was isolated using standard molecular biology techniques. The isolated TNFR2 Δ7 product was amplified by PCR using the same primers and then sequenced (FIG. 6B). The sequence data contained the sequence CTCTCTTCCAATTGAGAAGCCCTCCTGC (nucleotides 777-804 of SEQ ID No: 11), which confirms that the SSO-induced TNFR2 Δ7 mRNA lacks exon 7 and that exon 6 is joined directly to exon 8...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.

Description

[0001]This application is a continuation-in-part of U.S. application Ser. No. 11 / 595,485, filed Nov. 10, 2006 which claims priority to U.S. Provisional application Ser. No. 60 / 862,350, filed Oct. 20, 2006, and U.S. Provisional application Ser. No. 60 / 735,429, filed Nov. 10, 2005, all of which are incorporated by reference herein in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from TNF receptors and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF-α and prevent TNF-α from signaling to cells.BACKGROUND OF THE INVENTION[0003]TNF-α is a pro-inflammatory cytokine that exists as a membrane-bound homotrimer and is released as a homotrimer into the circulation by the protease TNF-α converting enzyme (TACE). TNF-α is introduced into the circulation as a mediator of the inflammatory response to injury and infect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07H21/00A61K31/713C12N15/11A61K48/00C12N15/113
CPCC12N15/111C12N15/1138C12N2310/11C12N2310/315C12N2310/321C07H21/04C12N2310/346C12N2320/33C12N2310/3231C12N2310/3521A61K38/00A61P29/00Y02A50/30A61K48/00C07K14/7151C12N15/113C07K14/70578
Inventor SAZANI, PETER L.
Owner SANTARIS PHARMA AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com